Newsfeeds - Spark Newswire

3 minute read

News

Jazz Pharmaceuticals Announced Data from Phase 2/3 Trial of Rylaze in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASCO; Said Results Confirm the Interim Trial Analysis Presented in December 2021 American Society of Hematology Meeting

Today, 5:58 PM

azz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric

JAZZ

1 minute read

‘Marijuana Coalition Launches New Campaign Backing Cannabis Banking Reform To Promote Equity’ -Marijuana Moment Report

By Benzinga Newsdesk

Today, 5:58 PM

https://www.marijuanamoment.net/marijuana-coalition-launches-new-campaign-backing-cannabis-banking-reform-to-promote-equity/

ACB

2 minute read

FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals

By Nina Zdinjak

Today, 5:58 PM

The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel Concepts (doing business as Free State Oils), Hope Botanicals, Plantacea LLC (doing business as Kahm CBD

JAZZ

5 minute read

Jazz Pharma Highlights Will Present Data Showcasing Clinical Advancements Across Oncology Portfolio At American Society Of Clinical Oncology Jun. 3-7, Congress Of European Hematology Association Jun. 9-12

By Benzinga Newsdesk

Today, 5:58 PM

Key data includes ASCO oral presentation of data from the Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, May 12, 2022

JAZZ

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals

By Benzinga Insights

Today, 5:58 PM

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

JAZZ

1 minute read

Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate

By Vandana Singh

Today, 5:58 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired development and commercialization rights in the U.S., Europe, and other territories for Sumitomo Pharma’s investigational DSP-0187. DSP-0187…

JAZZ

1 minute read

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $208

By Benzinga Newsdesk

Today, 5:58 PM

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $210 to $208.

JAZZ

3 minute read

Jazz Pharmaceuticals And Sumitomo Pharma Announce Exclusive License Agreement To Develop And Commercialize DSP-0187; Sumitomo Pharma To Receive $50M Upfront Payment

By Bill Haddad

Today, 5:58 PM

Jazz licenses development and commercialization rights in U.S., Europe and other territories; Sumitomo Pharma retains rights in Japan, China and other Asia/Pacific territories Sumitomo Pharma to receive $50 million

JAZZ

1 minute read

Jazz Pharmaceuticals Q1 Adj. EPS $3.73 Misses $3.83 Estimate, Sales $813.72M Miss $853.52M Estimate

By Benzinga Newsdesk

Today, 5:58 PM

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $3.73 per share which missed the analyst consensus estimate of $3.83 by 2.61 percent. This is a 4.85 percent decrease over earnings of $3.92 per share

JAZZ

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 5:58 PM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC